Suchergebnisse - "Cook, Gordon"

PubPharm (15)

1

The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages : results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial

enthalten in: British journal of haematology | 2023

von Jenner, M. | Pawlyn, C. | Davies, F. | +16

2

Health-related quality of life in patients with relapsed or refractory multiple myeloma : treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial

enthalten in: British journal of haematology | 2021

von Plesner, T. | Dimopoulos, M. | Oriol, A. | +15

3

Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma : results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial

enthalten in: British journal of haematology | 2021

von Jackson, G. | Pawlyn, C. | Cairns, D. | +21

4

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+) : Interim analysis of an open-label randomised controlled trial

enthalten in: PLoS medicine | 2021

von Jackson, G. | Pawlyn, C. | Cairns, D. | +21

5

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma : a cytogenetic subgroup analysis of POLLUX

enthalten in: Blood cancer journal | 2020

von Kaufman, J. | Dimopoulos, M. | White, D. | +26

6

Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials

enthalten in: Blood | 2020

von Craig, Z. | Cook, G. | Pawlyn, C. | +13

CommentIn: Blood. 2020 Aug 27;136(9):1019-1021. - PMID 32853375

7

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma : extended follow-up of POLLUX, a randomized, open-label, phase 3 study

enthalten in: Leukemia | 2020

von Bahlis, N. | Dimopoulos, M. | White, D. | +16

8

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age : subgroup analysis of the phase 3 CASTOR and POLLUX studies

enthalten in: Haematologica | 2020

von Mateos, M. | Spencer, A. | Nooka, A. | +16

9

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI) : a multicentre, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Haematology | 2019

von Jackson, G. | Davies, F. | Pawlyn, C. | +20

10

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma : updated analysis of POLLUX

enthalten in: Haematologica | 2018

von Dimopoulos, M. | San-Miguel, J. | Belch, A. | +30